National Heart and Lung Institute, Imperial College London, London, UK.
Faculty of Applied Medical Sciences, Respiratory Therapy Department, Jazan University, Jazan, Saudi Arabia.
BMJ Open Respir Res. 2021 Sep;8(1). doi: 10.1136/bmjresp-2021-000948.
Dietary nitrate supplementation, usually in the form of beetroot juice, may improve exercise performance and endothelial function. We undertook a systematic review and meta-analysis to establish whether this approach has beneficial effects in people with respiratory disease.
A systematic search of records up to March 2021 was performed on PubMed, CINAHL, MEDLINE (Ovid), Cochrane and Embase to retrieve clinical trials that evaluated the efficacy of dietary nitrate supplementation on cardiovascular parameters and exercise capacity in chronic respiratory conditions. Two authors independently screened titles, abstracts and full texts of potential studies and performed the data extraction.
After full-text review of 67 papers, eleven (two randomised controlled trials and nine crossover trials) involving 282 participants met the inclusion criteria. Three were single dose; seven short term; and one, the largest (n=122), done in the context of pulmonary rehabilitation. Pooled analysis showed that dietary nitrate supplementation reduced systolic blood pressure (BP), diastolic BP and mean arterial pressure (mean difference (95% CI), -3.39 mm Hg (-6.79 to 0.01); p=0.05 and -2.20 mm Hg (-4.36 to -0.03); p=0.05 and -4.40 mm Hg (-7.49 to -1.30); p=0.005, respectively). It was associated with increased walk distance in the context of pulmonary rehabilitation (standardised mean difference (95% CI), 0.47 (0.11 to 0.83), p=0.01), but no effect was identified in short-term studies (0.08 (-0.32 to 0.49).
Dietary nitrate supplementation may have a beneficial effect on BP and augment the effect of pulmonary rehabilitation on exercise capacity. Short-term studies do not suggest a consistent benefit on exercise capacity.
CRD42019130123.
膳食硝酸盐补充剂,通常以甜菜根汁的形式,可能会提高运动表现和内皮功能。我们进行了系统评价和荟萃分析,以确定这种方法是否对呼吸疾病患者有有益的影响。
我们在 PubMed、CINAHL、MEDLINE(Ovid)、Cochrane 和 Embase 上进行了系统检索,检索截至 2021 年 3 月的记录,以检索评估膳食硝酸盐补充剂对慢性呼吸道疾病心血管参数和运动能力影响的临床试验。两名作者独立筛选潜在研究的标题、摘要和全文,并进行数据提取。
在对 67 篇论文进行全文审查后,有 11 项(2 项随机对照试验和 9 项交叉试验)涉及 282 名参与者符合纳入标准。其中 3 项为单剂量;7 项为短期;其中一项(n=122)规模最大,是在肺康复的背景下进行的。汇总分析表明,膳食硝酸盐补充剂降低了收缩压(BP)、舒张压和平均动脉压(平均差值(95%置信区间),-3.39 毫米汞柱(-6.79 至 0.01);p=0.05 和-2.20 毫米汞柱(-4.36 至-0.03);p=0.05 和-4.40 毫米汞柱(-7.49 至-1.30);p=0.005)。它与肺康复背景下步行距离的增加有关(标准化均数差(95%置信区间),0.47(0.11 至 0.83),p=0.01),但短期研究未发现效果(0.08(-0.32 至 0.49)。
膳食硝酸盐补充剂可能对血压有有益的影响,并增强肺康复对运动能力的影响。短期研究并未表明对运动能力有一致的益处。
PROSPERO 注册号:CRD42019130123。